240 results on '"Schönland, Stefan"'
Search Results
2. In the era of Bortezomib-based Induction, intensification of Melphalan-based conditioning with Bortezomib does not improve Survival Outcomes in newly diagnosed Multiple Myeloma: a study from the Chronic Malignancies Working Party of the EBMT
3. Light chain mutations contribute to defining the fibril morphology in systemic AL amyloidosis
4. High-throughput electron tomography identifies centriole over-elongation as an early event in plasma cell disorders
5. Carfilzomib, lenalidomide and dexamethasone followed by a second ASCT is an effective strategy in first relapse multiple myeloma: a study on behalf of the Chronic malignancies working party of the EBMT
6. An early post-transplant relapse prediction score in multiple myeloma: a large cohort study from the chronic malignancies working party of EBMT
7. Healthcare Resource Utilization and Cost-of-Illness in Systemic Light Chain (AL) Amyloidosis in Europe: Results From the Real-World, Retrospective EMN23 Study
8. Common transthyretin-derived amyloid fibril structures in patients with hereditary ATTR amyloidosis
9. The management of light chain (AL) amyloidosis in Europe: clinical characteristics, treatment patterns, and efficacy outcomes between 2004 and 2018
10. Safety and efficacy of autologous stem cell transplantation in dialysis-dependent myeloma patients—The DIADEM study from the chronic malignancies working party of the EBMT
11. Birtamimab plus standard of care in light-chain amyloidosis: the phase 3 randomized placebo-controlled VITAL trial
12. Allogeneic hematopoietic stem cell transplantation for adult HLH: a retrospective study by the chronic malignancies and inborn errors working parties of EBMT
13. Autologous hematopoietic cell transplantation for relapsed multiple myeloma performed with cells procured after previous transplantation–study on behalf of CMWP of the EBMT
14. Long-Term Results of Allogeneic Stem Cell Transplantation in Adult Ph- Negative High-Risk Acute Lymphoblastic Leukemia
15. Access to and affordability of CAR T-cell therapy in multiple myeloma: an EBMT position paper
16. A randomized phase 3 study of ixazomib–dexamethasone versus physician’s choice in relapsed or refractory AL amyloidosis
17. Cryo-EM structure of an ATTRwt amyloid fibril from systemic non-hereditary transthyretin amyloidosis
18. Monoklonale Gammopathie renaler Signifikanz (MGRS): Eine Übersicht.
19. Response to therapy with tafamidis 61 mg in patients with cardiac transthyretin amyloidosis: real-world experience since approval.
20. HOVON 104, long‐term follow‐up of bortezomib‐dexamethasone induction therapy followed by autologous stem cell transplantation in newly diagnosed AL amyloidosis patients.
21. Second allogeneic transplants for multiple myeloma: a report from the EBMT Chronic Malignancies Working Party
22. Outcomes of renal transplantation in patients with AL amyloidosis: an international collaboration through The International Kidney and Monoclonal Gammopathy Research Group
23. Search for AL amyloidosis risk factors using Mendelian randomization
24. Letermovir prophylaxis is effective in preventing cytomegalovirus reactivation after allogeneic hematopoietic cell transplantation: single-center real-world data
25. Pre-transplant EASIX and sepsis after allogeneic stem cell transplantation
26. Impaired in vitro growth response of plasma-treated cardiomyocytes predicts poor outcome in patients with transthyretin amyloidosis
27. Solid state NMR assignments of a human λ-III immunoglobulin light chain amyloid fibril
28. Upfront stem cell transplantation for newly diagnosed multiple myeloma with del(17p) and t(4;14): a study from the CMWP-EBMT
29. Sequence diversity of kappa light chains from patients with AL amyloidosis and multiple myeloma.
30. Prognostic Value of Standard Heart Failure Medication in Patients with Cardiac Transthyretin Amyloidosis.
31. Are Autologous Stem Cell Transplants Still Required to Treat Myeloma in the Era of Novel Therapies? A Review from the Chronic Malignancies Working Party of the EBMT
32. Cryo-EM reveals structural breaks in a patient-derived amyloid fibril from systemic AL amyloidosis
33. Role of mutations and post-translational modifications in systemic AL amyloidosis studied by cryo-EM
34. Tandem Autologous Stem Cell Transplantation Improves Outcomes in Newly Diagnosed Multiple Myeloma with Extramedullary Disease and High-Risk Cytogenetics: A Study from the Chronic Malignancies Working Party of the European Society for Blood and Marrow Transplantation
35. A novel risk score to predict survival in advanced heart failure due to cardiac amyloidosis
36. Eight novel loci implicate shared genetic etiology in multiple myeloma, AL amyloidosis, and monoclonal gammopathy of unknown significance
37. Carpal tunnel syndrome and spinal canal stenosis: harbingers of transthyretin amyloid cardiomyopathy?
38. Outcome of Patients With Newly Diagnosed Systemic Light-Chain Amyloidosis Associated With Deletion of 17p
39. Outcome of a Salvage Third Autologous Stem Cell Transplantation in Multiple Myeloma
40. Venetoclax induces deep hematologic remissions in t(11;14) relapsed/refractory AL amyloidosis
41. Incidence of Second Primary Malignancies after Autologous Transplantation for Multiple Myeloma in the Era of Novel Agents
42. Improved outcomes after heart transplantation for cardiac amyloidosis in the modern era
43. AL amyloidosis with a localized B cell neoplasia
44. Local vs. systemic pulmonary amyloidosis—impact on diagnostics and clinical management
45. Comparison of Different Stem Cell Mobilization Regimens in AL Amyloidosis Patients
46. Baseline Characteristics Predicting Very Good Outcome of Allogeneic Hematopoietic Cell Transplantation in Young Patients With High Cytogenetic Risk Chronic Lymphocytic Leukemia - A Retrospective Analysis From the Chronic Malignancies Working Party of the EBMT
47. Premature Telomeric Loss in Rheumatoid Arthritis Is Genetically Determined and Involves Both Myeloid and Lymphoid Cell Lineages
48. AL amyloidosis patients with low amyloidogenic free light chain levels at first diagnosis have an excellent prognosis
49. A phase 1/2 study of the oral proteasome inhibitor ixazomib in relapsed or refractory AL amyloidosis
50. Response Assessment in Myeloma: Practical Manual on Consistent Reporting in an Era of Dramatic Therapeutic Advances
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.